HHS Secretary against using medical marijuana as alternative to opioid for treating pain

In a visit to the Dayton, Ohio area, HHS Secretary Alex Azar was asked by Yellow Spring News what role he’d envision for medical marijuana as an alternative to prescription opioids for pain relief.

“I would want to emphasize first that there really is no such thing as medical marijuana,” Azar said. “We have treatments that are approved by the Food and Drug Administration that are safe, that are proven to be safe and effective for pain, safe and effective for other conditions.”

He later added: “There is no FDA approved use of marijuana, a botanical plant.”

A recent study in the American Journal of Public Health found after legalization of marijuana in Colorado, opioid-related deaths dropped by 6.5 percent. An earlier study found the availability of medical marijuana in states between 2010 and 2013 changed prescribing patterns among Medicare Part D beneficiaries, especially on pain, with 1,826 fewer daily doses filled annually per physician. Overall, Medicare Part D spending in those states fell by a combined $165.2 million in 2013, but the drug remains classified as having no accepted medical use by the Drug Enforcement Agency.

Azar did indicate his agency wants to expand use of non-opioid pain treatments.

“Over $750 million just in 2019 alone is going to be dedicated to the National Institutes of Health working in a public-private partnership to try developing the next generations of pain therapies that are not opioids, as well as to develop the best evidence around alternative ways of treating pain that do not involve opioids,” Azar said. “So that’s where our focus is.”

Read more at the link below:

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

Compensation for heart specialists continues to climb. What does this say about cardiology as a whole? Could private equity's rising influence bring about change? We spoke to MedAxiom CEO Jerry Blackwell, MD, MBA, a veteran cardiologist himself, to learn more.

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals. 

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”